top of page
Piotr Witkowski Laboratory
since 2009
Pancreatic Islets
Kidney Transplantation
Immune Regulatory T Cell Therapy
WELCOME TO
THE FOREFRONT
October , 2023
Stacy's remarkable journey with insulin independence began over nine years ago following her islet transplantation. Stacy has experienced a newfound freedom from the constant concern about her blood sugar fluctuations. Her story is a testament to the transformative impact of islet transplantation in providing long-lasting stability and peace of mind.
As a dedicated transplant surgeon, I specialize in providing life-changing solutions for individuals in need of kidney and/or pancreas transplantation. My passion extends beyond the operating room; as a committed scientist, my focus lies in translational research, where I tirelessly test and introduce innovative technologies and procedures to enhance clinical practices.
Over the course of the last 15 years, my primary mission has been optimizing pancreatic islet transplantation. This intricate process, conducted as a minimally invasive procedure, aims to elevate the standard of care by achieving superior blood glucose control and granting patients the freedom from insulin dependence. I am driven by a steadfast commitment to advancing medical frontiers and improving the lives of those in my care.
Additionally, a key objective of my work is to reduce and eventually eliminate the necessity for toxic anti-rejection medications in transplant protection, a pursuit aligned with the coveted goal of inducing immunologic tolerance—often referred to as the Holy Grail of transplantation.
In pursuit of this mission, I am spearheading the development of a groundbreaking cellular therapy centered around ex-vivo expanded T regulatory cells (Tregs). Our clinical laboratory has successfully optimized the production of Tregs, paving the way for a novel therapeutic approach. This groundbreaking therapy not only holds promise for transplant patients but also extends its potential benefits to individuals grappling with autoimmune disorders such as type 1 diabetes, Crohn's disease, multiple sclerosis, or rheumatoid arthritis.
Furthermore, my team and I are actively conducting multiple clinical trials, exploring diverse approaches aimed at enhancing outcomes in both kidney and pancreatic islet transplantation. These trials represent our commitment to pushing the boundaries of medical science and offering transformative solutions to patients facing complex health challenges.
For more details, see links above for Diabetes, Pancreatitis and Kidney Tx.
Thank you for your interest in our research.
Piotr Witkowski M.D. Ph.D.
Professor of Surgery
Director, Pancreas and Pancreatic Islet Transplantation Program
Director, Transplant Surgery Fellowship Program
Director, Polish-American Transplant Center
Transplantation Institute
University of Chicago Medicine
bottom of page